NorthWest Biotherapeutics Inc (NWBO)

[pfort1]

Question for Pyrr

These information arm data are simply unsubstantiated without a concurrent control group. It doesn't matter if the ePD mOS is 20 months, neither the market nor the greater health community will credit DCVax-L with the ability to procure a survival advantage unless such data comes from a randomized trial.

The "indeterminates" showed 25% increase (from slight residual tumor--see criteria) or any size new lesion at baseline, but who after being followed up 2 months later showed either regression of either or stable disease in either, or a little growth in either. I said, well, if they scanned them again at 6 months like is often done in studies to determine psPD, then many of those indeterminates would no longer be indeterminate but properly split into ePD or psPD.

I assume L had proper guidance on structuring the trials. Then what is the possible explanation for not performing a randomized trial and scanning the "indeterminates" again at 6 months if such would lead to a definitive conclusion?

Incidentally - I'm lightening up my position in the stock.